Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notice of Extraordinary General Meeting of Cyxone

Shareholders in Cyxone AB (publ.), 559020-5471, are hereby invited to an extraordinary general meeting at Setterwalls Advokatbyrå AB, Stortorget 23, in Malmö, on Monday, December 11, 2017 at 10:00AM.Right to participate and registrationShareholders who wish to participate in the extraordinary general meeting (EGM) shall: · be included in the share register held by Euroclear Sweden AB on Tuesday, December 5, 2017; and · register with the company by Tuesday, December 5, 2017 in writing to Cyxone AB, FAO Kjell Stenberg, Adelgatan 21, 211 22 Malmö; by email to kjell.g.stenberg@cyxone.

Cyxone to propose new share issue to complete Rabeximod acquisition

As previously announced, Cyxone acquired Rabeximod from OxyPharma in June 2017. Rabeximod has undergone Phase 2 trials in patients with moderate to severe rheumatoid arthritis in which significant improvements in the condition's symptoms were discovered four weeks after the completion of the formal (12 week) trial period.Cyxone plans to conduct a new, so-called Phase 2B trial with Rabeximod under essentially identical conditions, but with the key difference that patients will be treated for twice as long (24 weeks) as the previous Phase 2 trial. Taking Rabeximod through a complete Phase

Dignitana publish interim financial report for Q3, 2017

Interim Financial Report - Summary: +--------------------------+----------+--------+-----------+---------+-------+|Key Ratios  | | | | | |+--------------------------+----------+--------+-----------+---------+-------+| | | | | | |+--------------------------+----------+--------+-----------+---------+-------+|Dignitana Group |Q3        |Q3      |Q1 |Q1 |Full || |2017 |2016 |-Q3        |-Q3      |year |

The Swedish Patent and Registration Office intends to grant Brighter's patent application.

The Swedish Patent and Registration Office intends to grant Brighter's patent application no. 1550571-2, regarding method and device for logging drug injections made by a medical device with injector. The patent covers a unique method for identifying whether an injection has occurred or not. After being registered in Sweden, the patent will be expanded to additional markets. – Over the years, Brighter has built an strong IP portfolio, and we are continuously strengthening it even further through continuous development within both current and new upcoming business areas. As part of the

Alfa Laval’s Capital Markets Day - summary of the business update

Alfa Laval’s Capital Markets Day, held today in Aalborg, Denmark, started with a presentation by Tom Erixon, President and CEO.  He talked, among other things, about the new, differentiated product platforms for gasketed plate heat exchangers (GPHE) as well as high-speed separators (HSS), that will be rolled out stepwise, starting from the end of this year.“Our ambition is to be the customers’ number one choice, which is why we are increasing our focus on R&D and speeding up product launches. This is a natural part of our overall efforts to ensure continued leadership,” said Tom Erixon. “

Prospectus regarding AcadeMedia’s rights issue is made public

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, HONG KONG, SWITZERLAND, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES BESIDES THOSE REQUIRED BY SWEDISH LAW. ADDITIONAL RESTRICTIONS APPLY, PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. Prospectus Prospectus regarding the rights issue in AcadeMedia has been approved and registered by Finansinspektionen and is now available at

Stillfront Group AB: Bytro Launches Call of War for Android in Early Access

PRESS RELEASE    Nov 23, 2017  Bytro Launches Call of War for Android in Early Access Bytro Labs, one of the Stillfront Group studios has launched its beta Android version of the highly successful browser game Call of War in Early Access on Google Play. Call of War is featured in the "Recent Launches" section of Google Play. The Android version, which is a native app, will allow players to play the strategy game Call of War on the go. Players can give orders to their armies, initiate research and order production of weapons from the convenience of their mobile phone. The game

Net Gaming completes acquisition of affiliate assets within the Nordics

Net Gaming has entered into an agreement to acquire several affiliate assets driving traffic throughout paid media channels - primarily within Sweden, but also in the UK.On November 10, 2017, Net Gaming announced the signing of a Letter of Intent to this effect. Net Gaming has now signed an agreement to acquire these affiliate assets. The acquired assets are growing fast. Currently, they are expected to generate quarterly revenues of approximately EUR 400,000, with an operating margin in the region of 50 percent. - I'm very happy that we are strengthening our position primarily within

BrainCool secures external financing of up to SEK 100 million and issues free warrants to its shareholders

BrainCool AB (publ) ("BrainCool") has signed an agreement relating to an investment of up to SEK 100 million. The capital will be used for launching BrainCool’s products in the US. The transaction is carried out through a private placement of convertible notes (the “Notes”) with warrants attached (the “Warrants”) in several tranches spread over 36 months (each, a “Tranche”). CEO Martin Waleij comments; -BrainCool has had a strong development. Based on our unique technology and innovative product development, we have created a broad portfolio of medical cooling products that have the

Interim report January-September 2017 Rabbalshede Kraft AB (publ)

Third-quarter production totaled 95,121 MWh (104,775) · Net sales amounted to KSEK 47,287 (50,364) · EBITDA totaled KSEK 25,006 (25,305) · EBIT was KSEK 1,696 (2,868) · Average income for wind-power production was SEK 497/MWh (481), of which electricity accounted for SEK 311/MWh (305) and electricity certificates and guarantees of origin for SEK 186/MWh (176).First nine months, January-September 2017 · Production from the Group’s wind farms during January-September amounted to 341,560 MWh (316,825).  · Net sales totaled KSEK 157,094 (144,809).· EBITDA amounted to KSEK 73,891 (65,601).

The European validation of Insplorion's main patent completed

Insplorion's main patent "Sensor Using Localized Surface Plasmon Resonance (LSPR)" was approved in Europe in May this year and has now been validated in Germany, France, Italy, Sweden, the Netherlands and the United Kingdom.The patent application was filed in May 2009 and has been approved in Japan, China, USA and Europe. For a European patent to be valid in the countries where it has been approved, it must be validated in each and every country. Validation, of the patent with publication number EP2435817, has been carried out in the countries considered to be most important from a

Fazer first in the world to introduce insect bread to grocery stores

One of the most spoken-about food revolutions is here. Fazer will be the first in the world to introduce insect bread to grocery stores. The novelty is called Fazer Sirkkaleipä (Fazer Cricket Bread). The first hand-baked cricket breads will become available in eleven Fazer in-store bakeries in Finland on Friday 24 November.Insect food is a significant global phenomenon that is about to land in Finland, too. Since last summer, Fazer has been developing insect bread to be included in the assortment of its in-store bakeries. The ban on selling insects as food was unexpectedly released in

Aker ASA: Invited into the restructuring of Norske Skog

Aker Capital AS ("Aker"), a wholly owned subsidiary of Aker ASA, and Oceanwood Capital Management LP ("Oceanwood"), have entered into an agreement to establish a company for the purpose of bidding for the shares in Norske Skog AS ("the Company"), a subsidiary of the listed Norske Skogindustrier ASA, in an auction process. The Company is the holding entity of Norske Skog's operating subsidiaries. Oceanwood is a creditor in the Company, and holds all of the NSF securitisation facility and a majority of the senior secured notes (the SSN). Aker and Oceanwood will be 50/50 owners of the new

Leading Nordic bitcoin broker seeks investment to boost European expansion

With expected revenue of €3M for the current fiscal year, the Finnish bitcoin broker Prasos aims to gain a leading position in Europe and reach €16M revenue in the next three years. To accomplish this, it is seeking funding on the Invesdor investment platform .The first stage of the public round started on the 9th of November. The investment range is from €750,057 to €2,499,959 and in 7 days the company raised 35% of the minimum target from existing owners and private investors. Now the round has been launched to public participation. "Since our

Agromino: Invitation to 3Q 2017 Results Presentation

Agromino will publish its report for the third quarter of 2017 on Thursday, 30th November 2017 at 08:00 CET. Analysts, investors and media are invited to attend a telephone conference that will be held at 10:00 CET on the same day.    Program: Simon Boughton, the CEO, and Konstantin Kotivnenko, the Executive Board member, will present and comment upon the results. There will also be an opportunity to ask questions. To participate in the telephone conference, please call one of the following numbers: DK: +45 35 445 575 FI: +358 981 710 492 UK +442 030 089 807 NO: +47 23

Board members and senior management in IRRAS have notified their intention to acquire shares in the Company

As previously announced by IRRAS AB (publ) (“IRRAS” or the "Company"), trading in the Company's shares on Nasdaq First North Premier commenced on 22 November 2017. The following members of the Board of Directors and senior management in IRRAS, as well as Serendipity Ixora AB, a major shareholder of IRRAS, have today notified the Company about their intention, directly or indirectly via related companies, to acquire shares in the Company today on Nasdaq First North Premier up to the amounts stated below for each party. Anders Wiklund, Chairman of the Board MSEK 0.5

Change in number of shares in Brighter AB.

Conversion of convertible notes into shares under the Convertible Notes issued under the financing agreement announced on April 26. The number of Notes converted on November 21, 2017 was 20. The number of Notes remaining under the third Tranche for future conversion is 58. The number of shares and the number of votes before the conversion was 64,124,569. Through the conversion, the number of shares and the number of votes have increased by 204 708. The total number of shares and the total number of votes after the conversion amount to 64,329,277. For terms and conditions of the Notes,

Researchers at Washington University report: DiviTum® can evaluate the biologic activity of blockbuster breast cancer drug after two weeks

Uppsala, Sweden, November 23, 2017. Results of a study from Washington University, St Louis, demonstrate that the DiviTum® can evaluate the biologic activity of Pfizer’s breast cancer drug palbociclib (Ibrance®) in just two weeks are published in the latest edition of the scientific journal Breast Cancer Research and Treatment. This shortening of the response evaluation window can improve outcome and increase quality of life for breast cancer patients.Led by Dr Cynthia Ma, the study investigated 50 women with breast cancer treated with standard endocrine therapy in combination with Ibrance®

DDM examines the possibility to issue senior secured bonds

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE REPUBLIC OF CYPRUS, HONG KONG, THE REPUBLIC OF ITALY, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.DDM Holding AG (First North: DDM) announces that one of its wholly owned indirect subsidiaries, DDM Debt AB (publ), has retained Carnegie Investment Bank to examine the possibility to issue a

DDM Debt examines the possibility to issue senior secured bonds

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE REPUBLIC OF CYPRUS, HONG KONG, THE REPUBLIC OF ITALY, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.DDM Debt AB (Nasdaq Stockholm: DDM2) announces that it has retained Carnegie Investment Bank to examine the possibility to issue a senior secured EUR denominated bond to support continued strong

Ahlsell acquires outlet for personal protective equipment and workwear in Umeå

Ahlsell Sverige AB has signed an agreement to acquire Jobline Umeå AB (Jobline) with annual sales of approximately SEK 26 million. Jobline offers workwear and protective equipment to small and medium-sized professional customers in Umeå and surroundings, north of Sweden. The customer offering consists to a large extent to strong brands from well-known suppliers. The company is privately owned and has eight employees. "Within workwear, Jobline has been successful for many years. Together, we can now offer our customers an even broader range of products and adjacent services. Our joint

Wilson Therapeutics AB (publ) Interim Report January 1–September 30, 2017

Ready for Phase 3July 1 – September 30, 2017 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 29.4 M (loss: 31.9) · Loss per share, before and after dilution, totaled SEK 1.14 (loss: 1,24) · At September 30, cash and cash equivalents amounted to SEK 277.1 M (416.5) January 1 – September 30, 2017 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 115.4 M (loss: 81.1) · Loss per share, before and after dilution, totaled SEK 4.49 (loss: 5.81) Significant events during the period January 1 – September 30, 2017 ·

Sedana Medical AB (publ) applies for registration of AnaConDa in Japan

Sedana Medical AB (”Sedana Medical” and “the Company”) has today submitted the application for registration of the medical device AnaConDa in Japan through its Japanese distributor.AnaConDa is a patented medical device with a unique technology making it possible to sedate patients with volatile anaesthetics in intensive care units, so called inhalation sedation. AnaConDa was approved by the South Korean authority K-FDA on February 23, 2017, the first country in Asia to do so. Sedana Medical has today applied to the Japanese authority, the Pharmaceutical and Medical Devices Agency, for the

There are no items matching the current filter
There are no more items matching the current filter
Back to top